

# CITATION REPORT

List of articles citing

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators

DOI: 10.1161/01.cir.98.23.2513  
Circulation, 1998, 98, 2513-9.

**Source:** <https://exaly.com/paper-pdf/29508682/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
850	Chick-embryo deaths traced to tincture of iodine. <b>1973</b> , 127, 581		
849	Calendar of Events. <b>1992</b> , 12, 167-170		
848	Problems with new criteria for diagnosis of diabetes mellitus. <b>1999</b> , 171, 108-108		2
847	Type 2 diabetic subjects without prior myocardial infarction are at the same risk of coronary events as non-diabetic subjects with prior myocardial infarction. <b>1999</b> , 20, 473-5		2
846	Associations of fat and cholesterol intake with serum lipid levels and cardiovascular disease: the EURODIAB IDDM Complications Study. <b>1999</b> , 107, 512-21		22
845	Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. <b>1999</b> , 159, 2661-7		308
844	Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy. <b>1999</b> , 159, 1033-4		46
843	Platelet function and lipid-lowering interventions. <b>1999</b> , 10, 357-67		35
842	Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <i>Circulation</i> , <b>1999</b> , 100, 1481-92	16.7	815
841	Dyslipidaemia and cardiovascular risk in diabetes. <b>1999</b> , 1, 189-98		24
840	Primaire preventie van hart- en vaatziekten via cholesterol?. <b>1999</b> , 37, 100-102		
839	Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes. <b>1999</b> , 84, 1004-10		23
838	Strategies for the management of diabetic dyslipidaemia. <b>1999</b> , 58 Suppl 1, 47-51; discussion 75-82		15
837	Nephropathy in patients with type 2 diabetes mellitus. <b>1999</b> , 341, 1127-33		580
836	Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. <i>Circulation</i> , <b>1999</b> , 100, 1134-46	16.7	1470
835	3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. <b>1999</b> , 452, 160-4		68
834	AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <b>1999</b> , 34, 1348-59		319

833	Diabetes and myocardial infarction. <b>1999</b> , 13, 331-43	1
832	Diabetes and the heart. <b>1999</b> , 60, 90-4	
831	Bibliography. Current world literature. <b>1999</b> , 6, 117-28	
830	Fibrates, dyslipoproteinaemia and cardiovascular disease. <b>1999</b> , 10, 561-74	110
829	Genetics and molecular biology. <b>1999</b> , 10, 365-368	
828	Dyslipidemia and atherosclerosis: how much more evidence do we need?. <b>1999</b> , 10, 383-6	4
827	Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. <b>2000</b> , 132, 780-7	66
826	Effects of Menopause and Estrogen Replacement Therapy or Hormone Replacement Therapy in Women With Diabetes Mellitus. <b>2000</b> , 7, 87-95	31
825	Translation research for chronic disease: the case of diabetes. <i>Diabetes Care</i> , <b>2000</b> , 23, 1794-8	14.6 81
824	The role of antihypertensive agents in preventing cognitive impairment. <b>2000</b> , 48, 1163-4	0
823	Status report of lipid-lowering trials in diabetes. <b>2000</b> , 11, 621-6	9
822	Emerging concepts in metabolic abnormalities associated with coronary artery disease. <b>2000</b> , 15, 416-21	44
821	Dyslipidemia in women with diabetes. <b>2000</b> , 7, 38-43	
820	Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus. <b>2000</b> , 16, 82-7	17
819	Coronary disease, dyslipidaemia and clinical trials in type 2 diabetes mellitus. <b>2000</b> , 17, 54-59	3
818	South Asians with diabetes mellitus do not receive lipid-lowering treatment despite an identical calculated risk of coronary heart disease compared with Caucasians. <b>2000</b> , 17, 77-80	3
817	MANAGING DYSLIPIDAEMIA IN TYPE 2 DIABETES IN PRIMARY CARE. <b>2000</b> , 17, S1-S8	1
816	Vascular disease prevention in patients with diabetes. <b>2000</b> , 2 Suppl 2, S25-36	5

815	Diabetic dyslipidaemia. <b>2000</b> , 2 Suppl 1, S31-6	34
814	Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?. <b>2000</b> , 2, 263-70	2
813	Potential interaction between troglitazone and atorvastatin. <b>2000</b> , 25, 279-82	9
812	Diabetes mellitus and coronary heart disease--from prevention to intervention: Part I. <b>2000</b> , 30, 351-9	8
811	Clinical trials and clinical practice--bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes. <b>2000</b> , 30, 483-91	3
810	Cardiovascular disease prevention practices by U.S. Physicians for patients with diabetes. <b>2000</b> , 15, 220-8	53
809	Cardiovascular risk in diabetes: a brief review. <b>2000</b> , 14, 108-15	68
808	Focus for the new millennium--diffuse coronary artery disease and new paradigms in cardiovascular medicine. <b>2000</b> , 9, 10-16	4
807	Current concepts and controversies in the pathogenesis, prevention, and treatment of the macrovascular complications of diabetes. <b>2000</b> , 135, 437-43	8
806	Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). <b>2000</b> , 85, 1395-400	76
805	Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). <b>2000</b> , 86, 309-12	309
804	Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. <b>2000</b> , 84, 357-60	29
803	Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. <b>2000</b> , 20, 823-9	147
802	Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. <b>2000</b> , 93, 567-74	27
801	Evidence-based therapy for type 2 diabetes. The best and worst of times. <b>2000</b> , 107, 27-8, 31-4, 37-40, passim	5
800	Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. <b>2000</b> , 160, 1361-9	60
799	Managing cardiovascular risk in patients with diabetes. <b>2000</b> , 84 Suppl 1, i23-5:discussion i50	
798	Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. <i>Circulation</i> , <b>2000</b> , 102, 191-6	16.7 156

797	Diabetes--a common, growing, serious, costly, and potentially preventable public health problem. <b>2000</b> , 50 Suppl 2, S77-84	183
796	Secondary prevention after myocardial infarction: reducing the risk of further cardiovascular events. <b>2000</b> , 4, 82-91	4
795	Effects of pravastatin treatment on lipoprotein levels and composition in patients with type 2 diabetes mellitus and hypercholesterolemia. <b>2000</b> , 61, 107-118	1
794	Cardiovascular disease in diabetic patients. <b>2000</b> , 84, 81-93, viii	28
793	Novel lipid-regulating drugs. <b>2000</b> , 9, 2619-28	17
792	Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. <b>2000</b> , 60, 975-83	32
791	Management of coronary artery disease: therapeutic options in patients with diabetes. <b>2000</b> , 36, 355-65	184
790	The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system. <b>2000</b> , 2 Suppl 1, S7-12	21
789	Lipid therapy is beneficial for diabetes patients with and without cardiovascular disease. <b>2001</b> , 5, 27-28	
788	Treatment of Dyslipidaemia with Fluvastatin in Patients with Type 2 Diabetes Mellitus. <b>2001</b> , 21, 671-678	5
787	Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. <i>Diabetes Care</i> , <b>2001</b> , 24, 1422-7	14.6 186
786	Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus. <b>2001</b> , 18, 325-33	18
785	The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. <b>2001</b> , 111, 633-42	127
784	Fenofibrate decreased the rate of angiographic progression of CAD in patients with type 2 diabetes mellitus. <b>2001</b> , 5, 58-60	
783	Multiple factor indices of protection or risk towards disease. <b>2001</b> , 56, 200-6	1
782	Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?. <b>2001</b> , 142, 857-63	38
781	Lipid-lowering therapy in diabetes mellitus. <b>2001</b> , 58, 214-22	22
780	Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. <b>2001</b> , 357, 905-910	711

779	El infarto de miocardio en el diabético: implicaciones clínicas, pronósticas y terapéuticas en la era trombolítico-intervencionista. <b>2001</b> , 25, 311-320		2
778	Treatment of dyslipidemia in diabetes. <b>2001</b> , 30, 999-1010		12
777	HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. <b>2001</b> , 15, 1454-6		77
776	. <b>2001</b> ,		4
775	Diabetes mellitus type II. <b>2001</b> , 508-528		
774	Management of diabetic nephropathy. <i>Journal of the Royal Society of Medicine</i> , <b>2001</b> , 94, 210-7	2.3	14
773	Cardiovascular Complications in Proteinuric Diabetic Patients. 155-174		
772	Lipid Disorders in Diabetic Nephropathy. 175-192		1
771	Normocholesterolaemic dyslipidaemia: is there a role for fibrates?. <b>2001</b> , 174, 66-7		3
770	11. References. <b>2001</b> , 175, S84		
769	The use of fibrates and of statins in preventing atherosclerosis in diabetes. <b>2001</b> , 12, 611-7		17
768	Lipid-lowering trials in diabetes. <b>2001</b> , 12, 619-23		7
767	. <b>2001</b> , 8, 127-132		6
766	Cardiovascular disease in diabetes: prevention and intervention. <b>2001</b> , 8, 101-110		3
765	The adequacy of current diagnostic criteria for diabetes. <b>2001</b> , 8, 88-94		2
764	The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. <b>2001</b> , 161, 1717-23		369
763	Calculation of coronary risk in Type II diabetes. <b>2001</b> , 101, 681-682		1
762	Should Obese Type 2 Diabetic Patients be Treated with Insulin?. 94-112		6

761	Perspectives on vascular biology and diabetes. <b>2001</b> , 49, 100-3	0
760	Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. <b>2001</b> , 11, 474-490	5
759	Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy. <b>2001</b> , 11, 368-383	3
758	Actos (pioglitazone): a new treatment for type 2 diabetes. <b>2001</b> , 62, 411-6	2
757	Diabetes: statins, fibrates, or both?. <b>2001</b> , 3, 19-28	18
756	Drugs for cardiovascular risk reduction in the diabetic patient. <b>2001</b> , 1, 133-9	4
755	The current management of diabetic dyslipidaemia. <b>2001</b> , 38 Suppl 1, S15-9	3
754	What does the future hold for diabetic dyslipidaemia?. <b>2001</b> , 38 Suppl 1, S21-6	3
753	Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities. <b>2001</b> , 2, 118-122	16
752	Anti-atherogenic effects of fibrates in type 2 diabetes. <b>2001</b> , 2, 218-220	1
751	Treating type 2 diabetes â today's targets, tomorrow's goals. <b>2001</b> , 3, 3-10	11
750	Predicting CHD risk in patients with diabetes mellitus. <b>2001</b> , 18, 341-4	47
749	Dyslipidaemia and diabetes. <b>2001</b> , 18, 201-207	10
748	Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. <b>2001</b> , 88, 9H-15H	63
747	Developing a clinical strategy for cholesterol management in an era of unanswered questions. <b>2001</b> , 88, 25F-30F	2
746	Insulin resistance syndrome and type 2 diabetes mellitus. <b>2001</b> , 88, 38J-42J	40
745	High-density lipoprotein cholesterol and treatment guidelines. <b>2001</b> , 88, 41N-44N	6
744	Manipulating the vascular biology of coronary atherosclerosis in diabetes: new opportunities. <b>2001</b> , 137, 82-92	1

743	Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins. <b>2001</b> , 15, 211-26		23
742	Glycemic control in the prevention of diabetic complications. <b>2001</b> , 4, 24-37		18
741	Management of ischaemic heart disease in diabetic patients--is there a role for cardiac metabolic agents?. <b>2001</b> , 17, 153-8		9
740	Impaired endothelium-dependent vasodilation in type 2 diabetes mellitus and the lack of effect of simvastatin. <b>2001</b> , 52, 299-305		68
739	American Diabetes Association 60th Scientific Sessions, 2000: cardiovascular disease in diabetes. <i>Diabetes Care</i> , <b>2001</b> , 24, 399-404	14.6	4
738	Prevention and treatment of coronary heart disease: who benefits?. <i>Circulation</i> , <b>2001</b> , 104, 1688-92	16.7	23
737	Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes. <b>2001</b> , 8, 127-32		1
736	External Barriers to Diabetes Care: Addressing Personal and Health Systems Issues. <b>2001</b> , 14, 23-28		75
735	The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. <i>Diabetes Care</i> , <b>2001</b> , 24, 1815-20	14.6	218
734	The National Diabetes Education Program, changing the way diabetes is treated: comprehensive diabetes care. <i>Diabetes Care</i> , <b>2001</b> , 24, 617-8	14.6	32
733	Preventing Cardiovascular Complications of Type 2 Diabetes: Focus on Lipid Management. <b>2001</b> , 19, 113-120		22
732	How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?. <i>Diabetes Care</i> , <b>2001</b> , 24, 45-50	14.6	78
731	Treatment of dyslipoproteinemia in the metabolic syndrome. <b>2001</b> , 109, S548-59		12
730	The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. <i>Diabetes Care</i> , <b>2001</b> , 24, 1335-41	14.6	113
729	Polypharmacy in Elderly Patients With Diabetes. <b>2002</b> , 15, 240-248		32
728	Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. <b>2002</b> , 51, 2596-603		60
727	Lipids and diabetes mellitus: a review of therapeutic options. <b>2002</b> , 18 Suppl 1, s58-74		3
726	New strategies for the treatment of diabetic dyslipidemia. <i>Diabetes Care</i> , <b>2002</b> , 25, 1237-9	14.6	11



725	The impact of outpatient diabetes management on serum lipids in urban African-Americans with type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 9-15	14.6	19
724	Diabetic patients detected by population-based stepwise screening already have a diabetic cardiovascular risk profile. <i>Diabetes Care</i> , <b>2002</b> , 25, 1784-9	14.6	94
723	Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. <i>Circulation</i> , <b>2002</b> , 105, 32-40	16.7	281
722	Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. <b>2002</b> , 22, 799-804		68
721	Protecting the kidneys and cardiovascular system in type 2 diabetes. <b>2002</b> , 2, 77-79		0
720	Vascular disease and survival in patients with type 2 diabetes and nephropathy. <b>2002</b> , 2, 137-142		1
719	Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity. <b>2002</b> , 87, 2283-9		40
718	The management of special patient populations. <b>2002</b> , 4, F19-F23		
717	Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. <b>2002</b> , 162, 273-9		116
716	Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). <b>2002</b> , 162, 2597-604		441
715	Lipids in type 2 diabetes. <b>2002</b> , 2, 59-66		12
714	Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. <b>2002</b> , 287, 2542-51		379
713	Optimal allocation of resources across four interventions for type 2 diabetes. <b>2002</b> , 22, S80-91		30
712	Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. <i>Diabetes Care</i> , <b>2002</b> , 25, 1211-6	14.6	86
711	Recognising and treating the diabetic patient in cardiovascular care. <b>2002</b> , 1, 171-81		3
710	Review: Type 2 diabetes: how far have we come?. <b>2002</b> , 2, 446-449		1
709	Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. <b>2002</b> , 287, 2570-81		1786
708	Response to Lamotte et Al. "A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.". <i>Diabetes Care</i> , <b>2002</b> , 25, 1899-900	14.6	1

707	Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol. <b>2002</b> , 9, 89-95		6
706	Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. <i>Diabetes Care</i> , <b>2002</b> , 25, 718-23	14.6	186
705	Clinical trial evidence for cardiovascular risk reduction in type 2 diabetes. <b>2002</b> , 16, 24-43		3
704	Atherogenic Lipid Phenotype and Lipoprotein (a) in Diabetes. <b>2002</b> , 12, 243-259		3
703	. <b>2002</b> , 9, 89-95		10
702	A diabetes report card for the United States: quality of care in the 1990s. <b>2002</b> , 136, 565-74		426
701	National diabetes education program: teaming up to prevent diabetes and its complications. <b>2002</b> , 42, 802-4		
700	Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. <b>2002</b> , 14, 197-204		49
699	Fibrates and coronary heart disease reduction in diabetes. <b>2002</b> , 9, 312-322		8
698	Lipid-lowering therapy in people with type 2 diabetes. <b>2002</b> , 13, 617-23		13
697	Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. <i>Diabetes Care</i> , <b>2002</b> , 25, 148-98	14.6	527
696	Diabetes and cardiovascular disease. <b>2002</b> , 53, 245-67		111
695	Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. <b>2002</b> , 112, 603-9		80
694	Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. <b>2002</b> , 40, 946-53		272
693	Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. <b>2002</b> , 347, 1342-9		274
692	Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. <b>2002</b> , 62, 1909-44		86
691	Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. <b>2002</b> , 51, 2377-86		145
690	Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. <b>2002</b> , 51, 1120-7		46

689 Ramipril reduces the risk of developing diabetes in high-risk people. **2002**, 6, 63-64

688 Acute myocardial infarction in the elderly with diabetes. **2002**, 31, 327-39

9

687 Diabetes mellitus and cardiovascular disease. **2002**, 13, 15-30

10

686 Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. **2002**, 24, 1426-38

9

685 Insulin resistance, ADMA levels, and cardiovascular disease. **2002**, 287, 1451-2

23

684 [Diabetic dyslipidemia: assessment and treatment]. **2002**, 119, 260-4

2

683 [Prevention and treatment of ischemic heart disease in patients with diabetes mellitus]. **2002**, 55, 975-86

8

682 Diabetic dyslipidaemia. **2002**, 2, S12-S17

7

681 Chronic Complications of Diabetes. **2002**, 95, 30-34

1

680 Cardiovascular events in patients with type 2 diabetes. **2002**, 2, S4-S8

679 [Management of cardiovascular risk factors in type 2 diabetes mellitus]. **2002**, 59, 415-21

678 Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors. **2002**, 59, 1173-9; quiz 1180-2

7

677 Effective diabetes care: a need for realistic targets. **2002**, 324, 1577-80

64

676 Reappraisal of the pharmacologic approach to treatment of type 2 diabetes mellitus. **2002**, 90, 42G-50G

140

675 Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. **2002**, 90, 55i-61i

65

674 The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. **2002**, 16, 123-32

41

673 Diabetes and macrovascular disease. **2002**, 16, 235-45

79

672 Considerations for treating dyslipidemia in special diabetic populations. **2002**, 18, 88-95

0

671	Cardiovascular disease: much more aggressive in patients with type 2 diabetes. <b>2002</b> , 4, 134-42	24
670	Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes. <b>2002</b> , 2, 396-402	16
669	Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. <b>2002</b> , 32, 429-36	72
668	Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. <b>2002</b> , 4 Suppl 1, S5-12	34
667	Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. <b>2002</b> , 4, 255-61	56
666	The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. <b>2002</b> , 4, 415-23	111
665	Diabetes in the elderly: problems of care and service provision. <b>2002</b> , 19 Suppl 4, 66-72	9
664	Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. <b>2002</b> , 19, 201-11	81
663	Dyslipidaemia in type 2 diabetes: a panel discussion. <b>2002</b> , 19, S1-S6	1
662	Poor lipid control in type-2 diabetics with and without ischemic heart disease. <b>2003</b> , 21, 217-20	10
661	Diabetic dyslipidaemia: from basic research to clinical practice. <b>2003</b> , 46, 733-49	613
660	Lipid abnormalities in the metabolic syndrome. <b>2003</b> , 3, 65-72	12
659	[Normalization of blood pressure and lipids in patients with diabetes]. <b>2003</b> , 98, 368-76	
658	Cardiovascular complications of diabetes: prevention and management. <b>2003</b> , 5, 22-37	5
657	REFERENCES. <b>2003</b> , 41, S77-S91	
656	The diabetes epidemic: can we stop the spread?. <b>2003</b> , 23, 1227-31	4
655	Compliance with clinical practice guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvement. <b>2003</b> , 23, 659-65	52
654	Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. <b>2003</b> , 92, 1379-83	248

653	Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome. <b>2003</b> , 91, 14B-22B	60
652	Treatment for patients with the metabolic syndrome. <b>2003</b> , 91, 29E-39E	71
651	Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. <b>2003</b> , 92, 27J-33J	95
650	Effects of Atorvastatin on LDL sub-fractions and peroxidation in type 1 diabetic patients: a randomised double-blind placebo-controlled study. <b>2003</b> , 19, 478-86	7
649	DIABETES JOURNAL WATCH The Heart Protection Study and diabetes. <b>2003</b> , 20, 5-7	1
648	Guidelines for improving the care of the older person with diabetes mellitus. <b>2003</b> , 51, S265-80	531
647	Management of lipids in patients with diabetes. <b>2003</b> , 5 Suppl 1, S3-9	1
646	Metabolic syndrome - a new risk factor of coronary heart disease?. <b>2003</b> , 5, 359-70	25
645	Screening for Type 2 diabetes--should it be now?. <b>2003</b> , 20, 175-81	40
644	Prediction of cardiovascular risk in people with diabetes. <b>2003</b> , 20, 515-27	19
643	Development and validation of the hyperlipidemia: attitudes and beliefs in treatment (HABIT) survey for physicians. <b>2003</b> , 18, 984-90	9
642	Treatment options for patients with the metabolic syndrome. <b>2003</b> , 15, 361-70	8
641	Tratamiento farmacológico del riesgo cardiovascular metabólico. <b>2003</b> , 8, 6382-6395	
640	Preventing cardiovascular disease in diabetes and glucose intolerance: evidence and implications for care. <b>2003</b> , 30, 569-92	13
639	The Heavy Burden of Cardiovascular Disease in Type 2 Diabetes. <b>2003</b> , 1-10	
638	Statin-fibrate combination: therapy for hyperlipidemia: a review. <b>2003</b> , 19, 155-68	139
637	Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. <b>2003</b> , 43, 1244-56	37
636	Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. <b>2003</b> , 167, 293-302	41

635	Long-term statin use and psychological well-being. <b>2003</b> , 42, 690-7		107
634	Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. <i>Diabetes Care</i> , <b>2003</b> , 26, 2713-21	14.6	254
633	Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. <b>2003</b> , 115 Suppl 8A, 24S-28S		93
632	Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor. <b>2003</b> , 115, 122-8		6
631	Lipid management and the elderly. <b>2003</b> , 6, 128-33; quiz 134-5		4
630	Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. <i>Circulation</i> , <b>2003</b> , 108, 1655-61	16.7	342
629	What are the odds at ASCOT today?. <b>2003</b> , 361, 1144-5		13
628	MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. <b>2003</b> , 361, 2005-16		2185
627	New developments in type 2 diabetes mellitus: combination therapy with a thiazolidinedione. <b>2003</b> , 25, 1895-917		13
626	Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. <b>2003</b> , 25 Suppl B, B4-31		48
625	From cholesterol levels to risk analysis: the revolution of the Heart Protection Study. <b>2003</b> , 1253, 217-222		
624	Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey. <b>2003</b> , 29, 241-9		13
623	Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events?. <b>2003</b> , 29, 470-6		34
622	Cardiovascular disease in patients who have diabetes. <b>2003</b> , 21, 399-413, vii		26
621	Mechanisms underlying endothelial dysfunction in diabetes mellitus: therapeutic implications. <b>2003</b> , 2, 293-304		35
620	Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. <b>2003</b> , 52, 803-11		191
619	Preventing macrovascular disease in patients with type 2 diabetes mellitus. <b>2003</b> , 3, 283-97		14
618	The role of lipids in the development of diabetic microvascular complications: implications for therapy. <b>2003</b> , 3, 325-38		36

617	Review: The management of stable angina in diabetes. <b>2003</b> , 3, 18-25		2
616	Dietary fat predicts coronary heart disease events in subjects with type 2 diabetes. <i>Diabetes Care</i> , <b>2003</b> , 26, 619-24	14.6	25
615	The Metabolic Syndrome: Targeting Dyslipidaemia to Reduce Coronary Risk. <b>2003</b> , 10, 121-128		20
614	Dyslipidemia in patients with type 2 diabetes. relationships between lipids, kidney disease and cardiovascular disease. <b>2003</b> , 41, 1174-81		35
613	Identification and management of diabetic nephropathy in the diabetes clinic. <i>Diabetes Care</i> , <b>2003</b> , 26, 1806-11	14.6	24
612	Statin Treatment in Diabetic Subjects: What the Heart Protection Study Shows. <b>2003</b> , 21, 151-152		1
611	DAIS: how it relates to other lipid intervention studies in diabetes. <b>2003</b> , 3, 212-215		
610	LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. <b>2003</b> , 23, 853-8		146
609	Walking: the best medicine for diabetes?. <b>2003</b> , 163, 1397-8		19
608	Clinical trials of lipid-lowering medication in diabetes. <b>2003</b> , 3, 217-220		1
607	C-reactive proteins and chronic disease: what role does nutrition play?. <b>2003</b> , 18, 227-33		10
606	Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. <b>2003</b> , 19, 635-41		75
605	Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. <i>Diabetes Care</i> , <b>2003</b> , 26, 2335-40	14.6	227
604	Lipid management in patients with diabetes: translating guidelines into action. <i>Diabetes Care</i> , <b>2003</b> , 26, 1309-11	14.6	6
603	Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. <i>Diabetes Care</i> , <b>2003</b> , 26, 1796-801	14.6	36
602	Type 2 diabetes and coronary heart disease: we keep learning how little we know. <b>2003</b> , 23, 917-8		2
601	Treatment of diabetic dyslipoproteinemia. <b>2003</b> , 111, 239-45		28
600	Prevention of macrovascular complications. <b>2003</b> , 5, B21-B26		2

599	Diabetes mellitus and cardiovascular risk: just another risk factor?. <b>2003</b> , 5, F26-F32		3
598	Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. <b>2003</b> , 163, 922-8		41
597	Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease. <b>2003</b> , 5, 18-33		4
596	Type 2 diabetes is cardiovascular disease. <i>Journal of the Royal Society of Medicine</i> , <b>2003</b> , 96, 371-2	2.3	1
595	Early and more vigorous detection of diabetes. <b>2003</b> , 18, 103-7		5
594	. <b>2003</b> , 14, 329-334		8
593	Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. <b>2003</b> , 163, 33-40		114
592	Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?. <b>2003</b> , 14, 575-83		36
591	. <b>2003</b> , 10, 121-128		62
590	Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities. <b>2003</b> , 18, 479-85		5
589	The insulin resistance syndrome and coronary artery disease. <b>2003</b> , 14, 335-48		43
588	Diabetes and heart disease an evidence-driven guide to risk factors management in diabetes. <b>2003</b> , 11, 262-74		23
587	Aggressive lipid management for cardiovascular prevention: evidence from clinical trials. <b>2003</b> , 228, 769-78		10
586	Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells. <b>2003</b> , 10, 117-23		51
585	Type 2 Diabetes is Cardiovascular Disease. <i>Journal of the Royal Society of Medicine</i> , <b>2003</b> , 96, 371-372	2.3	
584	References. <b>2003</b> ,		
583	The control of lipids with a statin. <b>2004</b> , 15, 611-614		
582	Orlistat in Obese Patients with Type 2 Diabetes: A Retrospective Assessment of Weight Loss and Metabolic Effects. <b>2004</b> , 39, 37-42		2



581	Treating low HDL-cholesterol in normocholesterolaemic patients with coronary disease: statins, fibrates or horses for courses?. <b>2004</b> , 25, 716-9		1
580	Handbook of Clinical Nutrition and Aging. <b>2004</b> ,		4
579	Diabetes mellitus in coronary artery surgery: therapeutic strategies in the light of recent studies. <b>2004</b> , 52, 349-55		3
578	Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus. <b>2004</b> , 112, 269-77		9
577	[Therapeutic options in patients with diabetes mellitus type 2 and coronary artery disease: intensified secondary prevention versus percutaneous or surgical revascularization]. <b>2004</b> , 129, 1385-9		2
576	Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids--update on the background of the current guidelines. <b>2004</b> , 112, 493-503		23
575	Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. <b>2004</b> , 25, 10-6		457
574	Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971-2000. <b>2004</b> , 160, 531-9		100
573	Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2004</b> , 27, 468-73	14.6	33
572	Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. <i>Diabetes Care</i> , <b>2004</b> , 27, 1324-9	14.6	87
571	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <i>Circulation</i> , <b>2004</b> , 110, 227-39	16.7	4450
570	Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. <b>2004</b> , 164, 1627-32		91
569	Statins and stroke prevention. <b>2004</b> , 17 Suppl 1, 81-8		26
568	Treating dyslipidaemia in the patient with type 2 diabetes. <b>2004</b> , 6, C28-C33		6
567	Role of simvastatin as an immunomodulator in type 2 diabetes. <i>Diabetes Care</i> , <b>2004</b> , 27, 908-13	14.6	9
566	Lipids and lipoproteins in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2004</b> , 27, 1496-504	14.6	483
565	Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. <b>2004</b> , 20, 1253-68		214
564	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <b>2004</b> , 24, e149-61		181

563	Diabetes: preventing coronary heart disease in a high risk group. <b>2004</b> , 90 Suppl 4, iv18-21	11
562	Principles of Diabetes Mellitus. <b>2004</b> ,	
561	Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. <b>2004</b> , 90, 1398-403	61
560	Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine). <b>2004</b> , 20, 765-72	10
559	Pharmacological treatment of lipid disorders in diabetes. <b>2004</b> , 58, 36-39	
558	The relative importance of cardiovascular risk factors in type 2 diabetes. <b>2004</b> , 58, 20-24	
557	A review of the efficacy of rosuvastatin in patients with type 2 diabetes. <b>2004</b> , 58, 30-40	9
556	Obesity in youth: implications for the advanced practice nurse in primary care. <b>2004</b> , 16, 326-34	4
555	Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. <b>2004</b> , 4 Suppl 7, 13-53	284
554	Effects of diabetes on the vascular system: current research evidence and best practice recommendations. <b>2004</b> , 22, 2-11; quiz 12-3	9
553	Educating patients with diabetes about cardiovascular disease risk. <b>2004</b> , 19, 107-13	1
552	Pharmacologic treatment of type 2 diabetic dyslipidemia. <b>2004</b> , 24, 1692-713	27
551	A systematic critique of diabetes on the world wide web for patients and their physicians. <b>2004</b> , 73, 687-94	43
550	Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome. <b>2004</b> , 93, 18C-26C	137
549	Evolving targets for risk reduction in diabetes. <b>2004</b> , 27, 125-8	
548	Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. <b>2004</b> , 47, 1257-1265	89
547	Stroke in patients with diabetes mellitus. <b>2004</b> , 20, 268-87	79
546	Dyslipidemia in visceral obesity: mechanisms, implications, and therapy. <b>2004</b> , 4, 227-46	77

545	Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. <b>2004</b> , 4, 299-314	22
544	Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. <b>2004</b> , 20, 1087-94	11
543	Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. <b>2004</b> , 35, 2902-9	556
542	Importancia del colesterol ligado a lipoproteínas de alta densidad (cHDL) en la prevención del riesgo cardiovascular. Recomendaciones del Foro HDL. <b>2004</b> , 16, 262-280	
541	Management of metabolic syndrome: statins. <b>2004</b> , 33, 509-23, vi	7
540	Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial. <b>2004</b> , 65, 330-44	10
539	Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. <b>2004</b> , 58, 614-8	68
538	High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study. <b>2004</b> , 147, 239-45	44
537	Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. <b>2004</b> , 116 Suppl 5A, 47S-63S	25
536	Examining the dyslipidemia constellation: an interactive forum on new treatment advances. Introduction. <b>2004</b> , 116 Suppl 6A, 1S-2S	268
535	A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. <b>2004</b> , 6, 18-25	13
534	Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey. <b>2004</b> , 30, 327-33	10
533	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <b>2004</b> , 44, 720-32	1070
532	Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin. <b>2004</b> , 175, 369-76	18
531	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. <b>2004</b> , 364, 685-96	2928
530	Dyslipidemia in the metabolic syndrome. <b>2004</b> , 2, 3-34	1
529	Type 2 diabetes and the metabolic syndrome: National Cholesterol Education Program guidelines and supporting evidence. <b>2004</b> , 3, S12-4	2
528	Clinical trials and lipid guidelines for type II diabetes. <b>2004</b> , 44, 423-30	29

527	Phenotypes, genotypes and response to statin therapy. <b>2004</b> , 15, 387-92	29
526	Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. <b>2004</b> , 19, 480-7	14
525	CE Test: Diabetes ABCs: Do You Know Them, Get Them, Improve Them?. <b>2004</b> , 22, 460-461	
524	Diabetes ABCs: do you know them, get them, improve them?. <b>2004</b> , 22, 452-9; quiz 460-1	2
523	Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. <b>2004</b> , 107, 233-49	40
522	Regular screening in type 2 diabetes. A mnemonic approach for improving compliance, detecting complications. <b>2004</b> , 115, 19-20, 23-7	7
521	Management of dyslipidemia in patients with metabolic syndrome. <b>2004</b> , 44, 478-88; quiz 489-90	13
520	Importance and management of dyslipidemia in the metabolic syndrome. <b>2005</b> , 330, 295-302	24
519	Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. <b>2005</b> , 329, 292-305	64
518	Commentary: A new approach to atherogenic dyslipidemia. <b>2005</b> , 117, 13-6	
517	Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets. <b>2005</b> , 117, 17-20, 23-7	2
516	Screening for Diabetes Mellitus â The World Health Organization Perspective. <b>2005</b> , 105-123	
515	Lowering LDL Cholesterol: Where Is the End of the Journey?. <b>2005</b> , 5, 39-50	0
514	Torcetrapib/atorvastatin combination therapy. <b>2005</b> , 3, 789-820	25
513	Pravastatin reduces fibrinogen receptor gpIIb on platelet-derived microparticles in patients with type 2 diabetes. <b>2005</b> , 3, 1168-71	48
512	Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. <b>2005</b> , 7, 88-97	58
511	Usefulness of total cholesterol/HDL-cholesterol ratio in the management of diabetic dyslipidaemia. <b>2005</b> , 22, 26-31	28
510	Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. <b>2005</b> , 22, 1670-6	31

509	Dyslipidaemia in type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. <b>2005</b> , 22 Suppl 3, 6-10	9
508	Type 2 diabetes mellitus: a cardiovascular perspective. <b>2005</b> , 59, 798-816	38
507	Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. <b>2005</b> , 257, 531-9	58
506	Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?. <b>2005</b> , 63, 650-6	5
505	New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. <b>2005</b> , 30, 241-79	20
504	Rationale for new American Diabetes Association Guidelines: are national cholesterol education program goals adequate for the patient with diabetes mellitus?. <b>2005</b> , 96, 33E-36E	13
503	Comparison of efficacy and safety assessment of fluvastatin in patients or =65 years of age. <b>2005</b> , 96, 1142-8	8
502	Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. <b>2005</b> , 48, 856-61	119
501	Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. <b>2005</b> , 48, 1726-35	126
500	Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome. <b>2005</b> , 7, 457-64	5
499	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. <b>2005</b> , 4, 13	74
498	Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. <b>2005</b> , 4, 7	42
497	Statins research unfinished saga: desirability versus feasibility. <b>2005</b> , 4, 8	5
496	Strokes and diabetes. <b>2005</b> , 22, 215-221	2
495	Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. <b>2005</b> , 12, 77-84	38
494	Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. <b>2005</b> , 5, S1-S15	
493	. <b>2005</b> ,	1
492	Diabetes and Hypertension. <b>2005</b> , 307-328	

491	Diabetic Dyslipidemia. <b>2005</b> , 155-170		
490	Risk Reduction in Patients With Diabetes. <b>2005</b> , 205-223		0
489	Macrovascular risk factors in patients with diabetes: physician treatment strategies and extent of control. <b>2005</b> , 11, 172-9		5
488	From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes. <b>2005</b> , 5, 218-225		3
487	Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid. <b>2005</b> , 5, 344-350		1
486	Lipid management with statins in type 2 diabetes mellitus. <b>2005</b> , 39, 1714-9		5
485	Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. <b>2006</b> , 92, 746-51		9
484	Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. <i>Diabetes Care</i> , <b>2005</b> , 28, 888-94	14.6	439
483	Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. <b>2005</b> , 46, 2735-44		31
482	Pathophysiology of dyslipidaemia in the metabolic syndrome. <b>2005</b> , 81, 358-66		120
481	Prevalence and risks of undiagnosed diabetes mellitus in patients undergoing coronary artery bypass grafting. <i>Circulation</i> , <b>2005</b> , 112, 2397-402	16.7	90
480	Can diabetes management programs create sustained improvements in disease outcomes?. <b>2005</b> , 173, 1467-8		4
479	Screening for type 2 diabetes mellitus to prevent vascular complications: updated recommendations from the Canadian Task Force on Preventive Health Care. <b>2005</b> , 172, 177-80		26
478	CARDS on the table: should everybody with type 2 diabetes take a statin?. <b>2005</b> , 21, 357-62		9
477	The vascular endothelium in diabetes: a practical target for drug treatment?. <b>2005</b> , 9, 101-17		18
476	Cyclic relationships between diabetic nephropathy and cardiovascular risk factors. <b>2005</b> , 3, 203-12		
475	Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?. <i>Diabetes Care</i> , <b>2005</b> , 28, 101-7	14.6	122
474	Antiretroviral therapy-induced hyperlipidaemia. <b>2005</b> , 16 Suppl 1, 2-10; discussion 10-3, 41-3		2

473	Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. <i>Diabetes Care</i> , <b>2005</b> , 28, 337-442	14.6	260
472	Effect of pravastatin in people with diabetes and chronic kidney disease. <b>2005</b> , 16, 3748-54		129
471	Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. <b>2005</b> , 313, 557-62		23
470	Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. <b>2005</b> , 21, 665-82		89
469	Diabetes and cardiovascular risk markers. <b>2005</b> , 21 Suppl 1, S21-8		22
468	Prevention of stroke in patients with diabetes mellitus and the metabolic syndrome. <b>2005</b> , 20 Suppl 1, 24-34		17
467	Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. <b>2005</b> , 26, 1314-20		39
466	¿Hasta dónde hay que reducir el colesterol en el paciente de alto riesgo cardiovascular?. <b>2005</b> , 22, 318-331		
465	Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. <i>Circulation</i> , <b>2005</b> , 112, 2735-52	16.7	8005
464	Management of dyslipidemia in elderly diabetic patients. <b>2005</b> , 31 Spec No 2, 5S74-5S81		4
463	The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia. <b>2005</b> , 182, 367-74		83
462	Fibrates and coronary risk reduction. <b>2005</b> , 182, 199-207		24
461	Diabetic dyslipidaemia: effective management reduces cardiovascular risk. <b>2005</b> , 6, 37-43		3
460	The dyslipidemia of diabetes mellitus: giving triglycerides and high-density lipoprotein cholesterol a higher priority?. <b>2005</b> , 34, 27-48		22
459	¿Hasta dónde hay que reducir el colesterol en el paciente de alto riesgo cardiovascular?. <b>2005</b> , 22, 318-331		
458	The role of lipid management in diabetes. <b>2005</b> , 23, 153-64, vi		
457	Outcome studies in type 2 diabetes. <b>2005</b> , 21 Suppl 1, S41-8		5
456	Management of diabetic dyslipidemia: need for reappraisal of the goals. <b>2005</b> , 5, 83-91		7

455	Global cardiovascular risk : the role of plasma lipids. <b>2005</b> , 12, 125-33	
454	Adverse effects of statins : how should cardiologists and general physicians manage them in clinical practice?. <b>2005</b> , 12, 141-8	1
453	Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. <b>2005</b> , 7, 73-80	45
452	Increased risk for cardiovascular outcomes and effect of cholesterol-lowering pravastatin therapy in patients with diabetes mellitus in the pravastatin anti-atherosclerosis trial in the elderly (PATE). <b>2005</b> , 66, 48-65	2
451	Long-term risk reduction: who needs treatment?. <b>2005</b> , 68 Suppl 2, S15-22	3
450	Prevalence and control of dyslipidemia among persons with diabetes in the United States. <b>2005</b> , 70, 263-9	95
449	Regimen to increase HDL cholesterol levels may improve cholesterol profiles. Commentary 2. <b>2005</b> , 9, 106-7, 109-11	
448	Effect of risk-adjusted diabetes on mortality and morbidity after coronary artery bypass surgery. <b>2005</b> , 79, 1570-6	70
447	Impact of physicians' beliefs and practices on cholesterol levels in patients with type 2 diabetes: a longitudinal assessment. <b>2005</b> , 149, 104-11	5
446	Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. <b>2005</b> , 150, 859-70	64
445	A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. <b>2005</b> , 118, 276-84	198
444	The importance of tight glycemic control. <b>2005</b> , 118, 7S-11S	69
443	Quality of life after acute myocardial infarction: a comparison of diabetic versus non-diabetic acute myocardial infarction patients in Quebec acute care hospitals. <b>2005</b> , 3, 80	17
442	Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. <b>2005</b> , 65, 31-74	57
441	Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. <b>2005</b> , 65, 137-52	12
440	Diabetes and Dyslipidemia. <b>2005</b> , 329-347	
439	Diabetes Mellitus and Heart Disease. <b>2005</b> , 579-628	
438	The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. <b>2005</b> , 45, 1413-8	53



437	Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach. <b>2005</b> , 23, 193-210	8
436	Management of diabetic dyslipidemia. <b>2005</b> , 34, 1-25, v	29
435	A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?. <b>2005</b> , 4, 311-7	8
434	Diabetic dyslipidaemia: insights for optimizing patient management. <b>2005</b> , 21 Suppl 1, S29-40	24
433	Diabetes and Cardiovascular Disease. <b>2005</b> ,	6
432	Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. <b>2006</b> , 4, 445-59	34
431	Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological intervention. <b>2006</b> , 6, 15-40	20
430	Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control. <b>2006</b> , 22 Suppl 2, S15-26	7
429	A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects. <b>2006</b> , 7, 99-110	15
428	Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention; the American Academy of Neurology affirms the value of this guideline. <b>2006</b> , 37, 577-617	1174
427	Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality. <b>2006</b> , 7, 463-76	15
426	Contributions of fasting and postprandial plasma glucose levels to glycosylated hemoglobin and diabetes mellitus-related complications: Treating hyperglycemia with insulin. <b>2006</b> , 1, 148-157	
425	Importancia de la prevención cardiovascular en la diabetes mellitus: un reto pendiente. <b>2006</b> , 18, 139-145	
424	[What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?]. <b>2006</b> , 2, 51-74	5
423	Diabetic dyslipidemia. <b>2006</b> , 35, 491-510, vii-viii	167
422	The application of evidence-based principles of care in older persons (issue 2): management of lipid disorders. <b>2006</b> , 7, 173-9	7
421	Concentraciones de hemoglobina glucosilada A1c, lipoproteínas de baja densidad y valores de presión arterial en adultos diagnosticados previamente de diabetes mellitus tipo 2. <b>2006</b> , 53, 246-251	1
420	Morbimortalidad por cardiopatía isquémica en el paciente diabético. <b>2006</b> , 53, 405-417	1

419	Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?. <b>2006</b> , 66, 273-86		9
418	Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). <i>Diabetes Care</i> , <b>2006</b> , 29, 1478-85	14.6	409
417	Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. <b>2006</b> , 47, 1093-100		441
416	ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). <b>2006</b> , 47, e1-121		372
415	Fibrates after the FIELD study: Some answers, more questions. <b>2006</b> , 3, 166-71		10
414	Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. <b>2006</b> , 151, 273-81		93
413	Lipid and lipoprotein dysregulation in insulin resistant states. <b>2006</b> , 368, 1-19		205
412	Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study. <b>2006</b> , 67, 321-33		1
411	Lipid management reduces cardiovascular complications in individuals with diabetes and prediabetes. <b>2006</b> , 9, 102-7; quiz 108-9		6
410	Drugs share antidiabetic and antiatherosclerotic actions through "the common soil". <b>2006</b> , 66, 473-5		5
409	Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes. <b>2006</b> , 107, 11-20		21
408	Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control. <b>2006</b> , 110, 137-45		15
407	A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control. <b>2006</b> , 22 Suppl 2, S39-48		10
406	Management of type 2 diabetes in youth (part 2). <b>2006</b> , 20, 88-97		11
405	Evolving treatment paradigms for vascular risk reduction in type 2 diabetes. <b>2006</b> , 6, S1-S12		
404	Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack. <i>Circulation</i> , <b>2006</b> , 113,	16.7	347
403	Management of dyslipidemia in diabetes. <b>2006</b> , 14, 125-35		55
402	Potential role of statins and PPARs in rheumatoid arthritis. <b>2006</b> , 1, 259-274		2

401 Angioplastie coronaire. **2006**, 1, 1-8

400 Achieving the therapeutic benefits of Niaspan<sup>®</sup> in daily practice. **2006**, 8, F68-F73

3

399 The metabolic syndrome: risk factors and management. **2006**, 21, 306-13

18

398 Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. **2006**, 17, 653-8

12

397 Diabetes and cardiovascular disease: does sugar matter?. **2006**, 13, 99-102

396 When it comes to the FIELD study, what is...is. **2006**, 1, 275-281

0

395 Reassessment of cardiovascular risk in diabetes. **2006**, 17, 644-52

8

394 Diabetes and dyslipidaemia. **2006**, 8, 355-64

27

393 What's in the CARDS?. **2006**, 23, 711-4

2

392 Use of vascular risk-modifying medications for diabetic patients differs between physician specialties. **2006**, 23, 1117-23

8

391 Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia. **2006**, 36, 560-5

4

390 Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education Program. **2006**, 18, 524-33

9

389 [Experiences collected in more than 2,300 diabetics undergoing coronary artery bypass grafting: patients with a specific risk profile]. **2006**, 95 Suppl 1, i7-13

0

388 Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. **2006**, 49, 1881-92

223

387 The effect of diabetes and stroke at baseline and during follow-up on stroke mortality. **2006**, 49, 2309-16

27

386 Treatment of lipid disorders in patients with diabetes. **2006**, 8, 37-45

5

385 The CARDS trial: diabetic patients dealt a winning hand. **2006**, 8, 429-32

8

384 Field of confusion: future prospects for fibrate therapy in cardiovascular disease. **2006**, 8, 219-22

9

383	Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes. <b>2006</b> , 175, 36-41	1
382	High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy. <b>2006</b> , 1, 178-83	7
381	Management of lipid disorders. <b>2006</b> , 27, 142-8	
380	Modifications of coronary risk factors. <b>2006</b> , 97, 41G-52G	17
379	Identifying patients for aggressive cholesterol lowering: the risk curve concept. <b>2006</b> , 98, 1405-8	40
378	Clinical impact of a pharmacist-managed diabetes mellitus drug therapy management service. <b>2006</b> , 26, 248-53	60
377	The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. <b>2006</b> , 27, 1298-304	37
376	Preventive Cardiology. <b>2006</b> ,	
375	The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management. <b>2006</b> , 12, 1567-79	10
374	Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. <b>2006</b> , 290, H1264-70	74
373	Stroke prevention and statin treatment. <b>2006</b> , 28, 335-44	6
372	Statins for diabetic cardiovascular complications. <b>2006</b> , 4, 245-51	28
371	Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Review: Heart failure complicating acute myocardial infarction in patients with diabetes: the value of pathophysiology and management strategies. <b>2006</b> , 6, 191-196	869
369	Lipid-lowering therapy in type 2 diabetes: a review of the evidence. <b>2006</b> , 3, S10-S15	
368	Management of dyslipidemias in patients with diabetes and chronic kidney disease. <b>2006</b> , 1, 1090-9	47
367	Diabetes and coronary risk equivalency: what does it mean?. <i>Diabetes Care</i> , <b>2006</b> , 29, 457-60	14.6 40
366	Review: Comparing cardiovascular outcomes in diabetes studies. <b>2006</b> , 6, 111-118	4

365	Case Studies in Lipid Management. <b>2006</b> ,		o
364	Biochemistry of Atherosclerosis. <b>2006</b> ,		
363	Obesity and Diabetes. <b>2006</b> ,		4
362	Quality of diabetes care in the middle- and high-income group populace: the Delhi Diabetes Community (DEDICOM) survey. <i>Diabetes Care</i> , <b>2006</b> , 29, 2341-8	14.6	67
361	ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). <i>Circulation</i> , <b>2006</b> , 113, e166-286	16.7	468
360	The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). <i>Circulation</i> , <b>2006</b> , 114, 2850-70	16.7	286
359	REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. <b>2006</b> , 91, 383-92		120
358	Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. <b>2006</b> , 332, 1115-24		221
357	Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. <b>2006</b> , 27, 2323-9		77
356	Lipid Management in Type 2 Diabetes. <b>2006</b> , 24, 27-32		33
355	Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. <i>Diabetes Care</i> , <b>2006</b> , 29, 1220-6	14.6	410
354	Application of cytogenetic endpoints and comet assay on human lymphocytes treated with atorvastatin in vitro. <b>2008</b> , 43, 78-85		7
353	The state of lipid control in patients with diabetes in a public health care centre. <b>2007</b> , 19, 16-21		6
352	Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes. <b>2007</b> , 4, 53-61		6
351	The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003. <b>2007</b> , 23, 1423-30		17
350	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. <b>2007</b> , 13 Suppl 1, 1-68		446
349	Rational therapy of mixed dyslipidaemia in a patient with diabetes. <b>2007</b> , 7, 25-30		o
348	Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. <i>Circulation</i> , <b>2007</b> , 115, 1544-50	16.7	479

347	Gain in patients' knowledge of diabetes management targets is associated with better glycemic control. <i>Diabetes Care</i> , <b>2007</b> , 30, 1587-9	14.6	58
346	Mortality trends in men and women with diabetes, 1971 to 2000. <b>2007</b> , 147, 149-55		337
345	The Role of C-Reactive Protein in the Metabolic Syndrome and Diabetes Mellitus. <b>2007</b> , 17, 163-168		1
344	Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease. <b>2007</b> , 4, 125-139		
343	How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with the Metabolic Syndrome?. <b>2007</b> , 4, 177-183		
342	Agreement between self-reports and medical records was only fair in a cross-sectional study of performance of annual eye examinations among adults with diabetes in managed care. <b>2007</b> , 45, 876-83		42
341	Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS). <b>2007</b> , 49, 81-4		33
340	Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. <b>2007</b> , 77, 126-33		67
339	Exploring Disease Management Programs for Diabetes Mellitus. <b>2007</b> , 15, 73-81		3
338	Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. <b>2007</b> , 67 Suppl 1, 43-54		24
337	HumaPen Memoir: a novel insulin-injecting pen with a dose-memory feature. <b>2007</b> , 4, 793-802		18
336	Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. <b>2007</b> , 23, 1673-84		35
335	Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States. <b>2007</b> , 23, 2125-33		11
334	[Cardiovascular PAPPS 2005: a critical analysis]. <b>2007</b> , 39, 201-6		1
333	Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. <b>2007</b> , 67, 121-53		110
332	[Cardiovascular disease in diabetes mellitus: classical and non-classical risk factors]. <b>2007</b> , 51, 257-67		7
331	Integrated Primary Prevention of Cardiovascular Disease. 129-189		
330	[Evaluation of cardiovascular risk according to Framingham criteria in patients with type 2 diabetes]. <b>2007</b> , 51, 268-74		6

329	Statin use in Canadians: trends, determinants and persistence. <b>2007</b> , 98, 412-6	29
328	. <b>2007</b> ,	2
327	. <b>2007</b> ,	2
326	Prevention of Cardiovascular Events in Diabetic Patients. 223-239	
325	Dyslipidaemia in diabetic patients: time for a rethink. <b>2007</b> , 9, 609-16	19
324	Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS). <b>2007</b> , 24, 1313-21	27
323	Cardiovascular risk profile of subjects with known diabetes from the middle- and high-income group population of Delhi: the DEDICOM survey. <b>2008</b> , 25, 27-36	6
322	Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. <b>2007</b> , 37, 637-42	53
321	Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. <b>2007</b> , 99, 27B-40B	109
320	Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus. <b>2007</b> , 99, 96B-104B	30
319	Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus. <b>2007</b> , 99, 133B-140B	16
318	Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. <b>2007</b> , 99, 4i-20i	155
317	Paediatric diabetes: achieving practical, effective insulin therapy in type 1 and type 2 diabetes. <b>2007</b> , 96, 1560-70	13
316	Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors. <b>2007</b> , 8 Suppl 6, S6-13	14
315	Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors. <b>2007</b> , 8, 53-68	14
314	[Lowering LDL cholesterol. How much is enough?]. <b>2007</b> , 48, 319-26	
313	The cost-effectiveness of pharmacist-led treatment of cardiac risk in patients with type 2 diabetes. <b>2007</b> , 29, 541-5	15
312	Lipid goals in metabolic syndrome and diabetes. <b>2007</b> , 9, 286-95	2

311	SPARCL: the glimmer of statins for stroke risk reduction. <b>2007</b> , 9, 347-51	3
310	Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update. <b>2007</b> , 7, 208-17	12
309	Dyslipidemia in type 2 diabetes mellitus. <b>2007</b> , 7, 228-34	36
308	Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes. <b>2008</b> , 51, 1382-90	21
307	The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. <b>2008</b> , 51, 1731-40	49
306	Optimal treatment of the diabetic patient with multivessel disease. <b>2008</b> , 10, 272-84	1
305	Cardiometabolic risk management in type 2 diabetes and obesity. <b>2008</b> , 8, 345-52	6
304	The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes. <b>2008</b> , 31, 241-8	18
303	An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?. <b>2008</b> , 62, 799-809	53
302	A cardiologist view of vascular disease in diabetes. <b>2008</b> , 10, 279-92	12
301	Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. <b>2008</b> , 69, 45-51	14
300	Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. <b>2008</b> , 249, 225-235	5
299	Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. <b>2008</b> , 102, 41L-47L	22
298	Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral blood lymphocytes: standard and Fpg-modified comet assay. <b>2008</b> , 231, 85-93	55
297	Lípidos y enfermedad cerebrovascular. El papel de las estatinas. Nuevas opciones hipolipemiantes en investigación. <b>2008</b> , 208, 13-18	
296	Paraoxonase 1 and Postprandial Lipemia. <b>2008</b> , 129-138	
295	Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. <b>2008</b> , 2, 91-105	17
294	Diabetic dyslipidemia and the metabolic syndrome. <b>2008</b> , 2, 208-222	5



293	PROactive: time for a critical appraisal. <b>2008</b> , 29, 969-83		42
292	Postprandial lipemia: an under-recognized atherogenic factor in patients with diabetes mellitus. <b>2008</b> , 126, 3-12		50
291	Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). <b>2008</b> , 155, 712-7		103
290	National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002. <b>2008</b> , 156, 284-91		11
289	Early Improvements in insulin sensitivity and inflammatory markers are induced by pravastatin in nondiabetic subjects with hypercholesterolemia. <b>2008</b> , 390, 49-55		7
288	Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. <b>2008</b> , 30, 294-306		20
287	Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. <b>2008</b> , 199, 455-62		43
286	Type 2 diabetes mellitus: prevention of macrovascular complications. <b>2008</b> , 6, 323-41		21
285	Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. <b>2008</b> , 28, 1831-7		43
284	Standards of medical care in diabetes--2008. <i>Diabetes Care</i> , <b>2008</b> , 31 Suppl 1, S12-54	14.6	1381
283	Pharmacological regulation of dyslipoproteinaemia in insulin resistant states. <b>2008</b> , 6, 67-77		3
282	Prescribing practice of general practitioners in Northern Ireland for peripheral arterial disease. <b>2008</b> , 59, 57-63		4
281	Do people with diabetes need statins?. <b>2008</b> , 34, 664-73		0
280	Improved survival of diabetic foot ulcer patients 1995-2008: possible impact of aggressive cardiovascular risk management. <i>Diabetes Care</i> , <b>2008</b> , 31, 2143-7	14.6	98
279	Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. <b>2008</b> , 9, 669-76		15
278	The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvements. <b>2008</b> , 17, 250-9		5
277	Cardiovascular risk reduction among African Americans: a call to action. <b>2008</b> , 100, 18-26		13
276	Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. <b>2008</b> , 52, 136-44		61

275	Pharmacologic management of isolated low high-density lipoprotein syndrome. <b>2008</b> , 15, 377-88	13
274	Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. <b>2008</b> , 23, 502-11	36
273	Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. <b>2008</b> , 15, 142-6	15
272	The cholesterol hypothesis: questioned?. <b>2008</b> , 15, 292-5	
271	DIABETES MELLITUS: OLD ASSUMPTIONS AND NEW REALITIES. <b>2008</b> , 23-32	
270	Diabetes y consulta médica grupal en atención primaria: ¿Vale la pena el cambio?. <b>2009</b> , 137,	3
269	A risk management partnership. <b>2009</b> , 20, 86-90	7
268	Reduced high-density lipoprotein 2b in non-obese type 2 diabetic patients analysed by a microfluidic chip method in a case-control study. <b>2009</b> , 14, 619-23	8
267	Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. <b>2009</b> , 16, 94-112	204
266	Should all diabetic patients be treated with a statin?. <i>Diabetes Care</i> , <b>2009</b> , 32 Suppl 2, S378-83	14.6 12
265	Clinical insights from the Treating to New Targets trial. <b>2009</b> , 51, 487-502	5
264	The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia. <b>2009</b> , 11, 520-7	17
263	Managing diabetic dyslipidemia: beyond statin therapy. <b>2009</b> , 9, 11-7	17
262	Treatment of hypertension in metabolic syndrome: implications of recent clinical trials. <b>2009</b> , 9, 229-37	5
261	Interpreting clinical trials of diabetic dyslipidaemia: new insights. <b>2009</b> , 11, 261-70	6
260	Lipid modification in type 2 diabetes: the role of LDL and HDL. <b>2009</b> , 23, 681-5	67
259	Serum phosphorus and cardiovascular mortality in type 2 diabetes. <b>2009</b> , 122, 380-6	49
258	Rationale and design of a clinical trial to evaluate metformin and colestevam HCl as first-line therapy in type 2 diabetes and colestevam HCl in prediabetes. <b>2009</b> , 25, 2239-49	13

257	Stroke and Diabetes Mellitus. <b>2009</b> , 183-218		1
256	Insulin Resistance. <b>2009</b> ,		
255	Standards of medical care in diabetes--2009. <i>Diabetes Care</i> , <b>2009</b> , 32 Suppl 1, S13-61	14.6	1378
254	Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study. <b>2009</b> , 9, 299-308		5
253	Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. <b>2009</b> , 256, 1603-19		43
252	Existe-t-il un lien entre lâéquilibre glycémique et la morbi-mortalitéchez les diabétiques de type 2 de plus de 70 ans ? : Intérêt de la mise en place dâune première étude prospective. <b>2009</b> , 3, 203-206		7
251	Diabetes and cardiovascular disease prevention in older adults. <b>2009</b> , 25, 607-41, vii-viii		34
250	Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). <b>2009</b> , 206, 535-9		88
249	Cardiovascular manifestations of insulin resistance. <b>2009</b> , 16, e14-28		10
248	Obesity and diabetes: lipids, 'nowhere to run to'. <b>2009</b> , 116, 113-23		51
247	The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. <b>2009</b> , 121, 7-12		29
246	Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. <b>2010</b> , 91, 900-6		23
245	Status of diabetes care among community pharmacy patients with diabetes: analysis of the Medical Expenditure Panel Survey. <b>2010</b> , 50, 478-84		2
244	Statin use and depressive symptoms in a prospective study of community-living older persons. <b>2010</b> , 19, 942-8		18
243	Gender-specific aspects of treatment of cardiovascular risk factors in primary and secondary prevention. <b>2010</b> , 24, 699-705		11
242	Computerized history-taking as a tool to manage dyslipidemia. <i>Vascular Health and Risk Management</i> , <b>2010</b> , 6, 1039-46	4.4	9
241	Dificultades en la prescripci3n racional de insulina: La percepci3n de los m3dicos tratantes de enfermos diab3tico de atenci3n primaria de salud. <b>2010</b> , 138,		1
240	Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena?. <i>Vascular Health and Risk Management</i> , <b>2010</b> , 6, 665-9	4.4	18

239	Diabetes and the Brain. <b>2010</b> ,	3
238	High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease. <b>2010</b> ,	5
237	Quality of diabetes care at Armed Forces Hospital, Southern Region, Kingdom of Saudi Arabia, 2006. <b>2010</b> , 17, 129-34	3
236	Kosteneffektivität von Pioglitazon bei Patienten mit Typ-2-Diabetes und makrovaskulären Vorerkrankungen in Deutschland. <b>2010</b> , 5, 32-39	
235	Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome. <b>2010</b> , 122, 61-70	10
234	Ataque isquémico transitorio riesgo de trombosis cerebral en pacientes con diabetes: prevención y tratamiento. <b>2010</b> , 26, 403-407	
233	Does Treating Hyperlipidaemia with Medication Prevent Complications?. 241-255	
232	The Management of Peripheral Arterial Disease in Patients with Type 2 Diabetes. 393-402	
231	[Advances in cholesterol-lowering interventions]. <b>2010</b> , 57, 210-9	8
230	Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. <b>2010</b> , 138, 157-65	26
229	[Global therapy of diabetic dyslipidemia: benefits and new therapeutic approaches]. <b>2010</b> , 134, 406-11	5
228	Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. <b>2010</b> , 105, 1300-5	28
227	Utilization of lipid lowering medications among adults in the United States 1999-2006. <b>2010</b> , 208, 456-60	27
226	Standards of medical care in diabetes--2010. <i>Diabetes Care</i> , <b>2010</b> , 33 Suppl 1, S11-61	14.6 2438
225	An evaluation of diabetes-related measures of control after 6 months of clinical pharmacy specialist intervention. <b>2011</b> , 24, 332-8	21
224	Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease. <b>2011</b> , 58, 283-290	1
223	[Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease]. <b>2011</b> , 58, 283-90	2
222	Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <b>2011</b> , 42, 517-84	1148

221	Lipid control in patients with diabetes mellitus. <b>2011</b> , 8, 278-90	32
220	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. <b>2011</b> ,	6
219	Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. <b>2011</b> , 124, S35-53	58
218	Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus. <b>2011</b> , 149, 46-9	26
217	Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus. <b>2011</b> , 29, 47-70	18
216	Management of Elevated Cholesterol in the primary prevention Group of Adult Japanese (MEGA) Study assists the view that a fasting plasma glucose level $\geq 100$ mg/dL increases cardiovascular risk. <b>2011</b> , 2, 399-405	
215	Unit 3. Creating a risk-management partnership. <b>2011</b> , 22, 1-4	
214	Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population: National Health and Nutrition Examination Survey 2005-2008. <b>2011</b> , 12, 714-22	7
213	Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus. <b>2011</b> , 171, 1542-50	69
212	Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress. <b>2011</b> , 164, 598-606	37
211	Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. <i>Revista Espanola De Cardiologia Suplementos</i> , <b>2011</b> , 11, 29-35	0.2 1
210	Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. <b>2011</b> , 108, 3B-24B	212
209	Optimal treatment for coronary artery disease in patients with diabetes: percutaneous coronary intervention, coronary artery bypass graft, and medications. <b>2011</b> , 59, 6-13	1
208	Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial. <b>2011</b> , 10, 58	14
207	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. <b>2011</b> , 12, 1429-38	15
206	Combination lipid therapy in type 2 diabetes mellitus. <b>2011</b> , 12, 1393-403	1
205	Significance of LDL-C lowering therapy in diabetic patients. <b>2011</b> , 6, 389-399	2
204	Standards of medical care in diabetes--2011. <i>Diabetes Care</i> , <b>2011</b> , 34 Suppl 1, S11-61	14.6 2104

203	Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. <b>2011</b> , 12, 13-30		50
202	Lipids and diabetic retinopathy. <b>2012</b> , 12, 93-105		40
201	Lifestyle counseling in routine care and long-term glucose, blood pressure, and cholesterol control in patients with diabetes. <i>Diabetes Care</i> , <b>2012</b> , 35, 334-41	14.6	38
200	Naringin ameliorates atherogenic dyslipidemia but not hyperglycemia in rats with type 1 diabetes. <b>2012</b> , 59, 133-41		35
199	Small dense low-density lipoprotein particles: priority as a treatment target in Type 2 diabetes?. <b>2012</b> , 2, 65-74		1
198	Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs. <b>2012</b> , 91, 514-20		4
197	Statins are diabetogenic--myth or reality?. <b>2012</b> , 13, 1-10		71
196	Infradiagnosed complications of chronic diabetes mellitus: The value of systematic review in a single visit. <b>2012</b> , 59, 585-590		2
195	Infradiagnosed complications of chronic diabetes mellitus: the value of systematic review in a single visit. <b>2012</b> , 59, 585-90		2
194	Standards of medical care in diabetes--2012. <i>Diabetes Care</i> , <b>2012</b> , 35 Suppl 1, S11-63	14.6	1663
193	Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. <b>2012</b> , 52, 83-92		73
192	Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. <b>2012</b> , 7, e32785		136
191	Effects of rice bran oil on the blood lipids profiles and insulin resistance in type 2 diabetes patients. <b>2012</b> , 51, 15-8		36
190	Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients. <b>2012</b> , 5, 125-34		6
189	Diabetic cardiovascular disease: getting to the heart of the matter. <b>2012</b> , 5, 436-45		18
188	Did AIM-HIGH aim too low?. <b>2012</b> , 4, 1-2		6
187	Microvascular responsiveness in obesity: implications for therapeutic intervention. <b>2012</b> , 165, 544-60		37
186	Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. <b>2012</b> , 14, 30-9		7

185	Lipoprotein metabolism in patients with type 1 diabetes under intensive insulin treatment. <b>2013</b> , 12, 15		21
184	Pathology, pathophysiology, and treatment strategies of endocrine disorders and their cardiac complications. <b>2013</b> , 30, 245-62		1
183	Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. <b>2013</b> , 166, 199-207.e15		276
182	New therapeutic alternatives for the management of dyslipidemia. <b>2013</b> , 26, 528-40		2
181	La prévention primaire par les statines du risque cardiovasculaire des diabétiques : un mauvais procédé en place publique. <b>2013</b> , 2013, 9-15		
180	Tratamento com estatina no diabético tipo 2. <b>2013</b> , 8, 50-54		
179	Relationship between low-density lipoprotein levels on admission and 1-year outcome in patients with acute ST-segment-elevation myocardial infarction. <b>2013</b> , 29, 206-13		4
178	Standards of medical care in diabetes--2013. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 1, S11-66	14.6	2668
177	Three 15-min bouts of moderate postmeal walking significantly improves 24-h glycemic control in older people at risk for impaired glucose tolerance. <i>Diabetes Care</i> , <b>2013</b> , 36, 3262-8	14.6	64
176	Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 3297-304	14.6	19
175	Treat to goal: impact of clinical pharmacist referral service primarily in diabetes management. <b>2013</b> , 48, 656-61		4
174	Association of Medicare Part D medication out-of-pocket costs with utilization of statin medications. <b>2013</b> , 48, 1311-33		13
173	Reducing the risks of diabetes complications through diabetes self-management education and support. <b>2013</b> , 16, 74-81		36
172	Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. <b>2013</b> , 20, 1095-105		24
171	Benchmarking is associated with improved quality of care in type 2 diabetes: the OPTIMISE randomized, controlled trial. <i>Diabetes Care</i> , <b>2013</b> , 36, 3388-95	14.6	37
170	The Role of Statins in Diabetes Treatment. <b>2013</b> , 26, 156-164		6
169	Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients--a systematic review and meta-analysis. <b>2013</b> , 10, 157-70		8
168	Trends in low-density lipoprotein cholesterol goal achievement in high risk United States adults: longitudinal findings from the 1999-2008 National Health and Nutrition Examination Surveys. <b>2013</b> , 8, e59309		16

167	Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT study. <b>2013</b> , 20, 368-79	13
166	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. <b>2014</b> , 7, 169-83	106
165	Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. <b>2014</b> , 9, e111247	32
164	All-cause mortality in patients with type 2 diabetes in association with achieved hemoglobin A(1c), systolic blood pressure, and low-density lipoprotein cholesterol levels. <b>2014</b> , 9, e109501	16
163	[Levels of glycosylated hemoglobin and the difference in the cost of health care for diabetic patients: an econometric study]. <b>2014</b> , 142, 841-9	0
162	Rationale and design of the Miami Healthy Heart Initiative: a randomized controlled study of a community health worker intervention among Latino patients with poorly controlled diabetes. <b>2014</b> , 7, 115-26	18
161	The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus. <b>2014</b> , 20, 968-84	5
160	Statins, Diabetic Oxidative Stress and Vascular Tissue. <b>2014</b> , 183-190	1
159	Risk of vascular disease in premenopausal women with diabetes mellitus. <b>2014</b> , 36, 1924-1934	5
158	Comparison of LDL-cholesterol estimate using the Friedewald formula and the newly proposed de Cordova formula with a directly measured LDL-cholesterol in a healthy South African population. <b>2014</b> , 51, 672-9	21
157	Diabetes and Cardiovascular Disease. <b>2014</b> , 312-317	
156	Addressing statin adverse effects in the clinic: the 5 Ms. <b>2014</b> , 19, 533-42	19
155	Statins use and risk of depression: a systematic review and meta-analysis. <b>2014</b> , 160, 62-7	69
154	Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. <b>2014</b> , 45, 3754-832	921
153	Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes. <b>2014</b> , 8, 145-51	13
152	Standards of medical care in diabetes--2014. <i>Diabetes Care</i> , <b>2014</b> , 37 Suppl 1, S14-80	14.6 3373
151	Presence of diabetes does not matter for percutaneous coronary intervention outcomes with simple coronary lesions: can that be true?. <b>2014</b> , 63, 2119-2120	
150	Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. <b>2014</b> , 4, e005402	17



149	Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. <b>2015</b> , 14, 60	3
148	Hypertension and Dyslipidemia in Patients with Pre-Diabetes: Dietary and Other Therapies. <b>2015</b> , 157-179	
147	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <b>2015</b> , 9, S1-122.e1	293
146	Disparities in lipid control and statin drug use among diabetics with noncoronary atherosclerotic vascular disease vs those with coronary artery disease. <b>2015</b> , 9, 241-6	4
145	(8) Cardiovascular disease and risk management. <i>Diabetes Care</i> , <b>2015</b> , 38 Suppl, S49-57	14.6 206
144	Cardiovascular magnetic resonance imaging-based computational fluid dynamics/fluid-structure interaction pilot study to detect early vascular changes in pediatric patients with type 1 diabetes. <b>2015</b> , 36, 851-61	7
143	Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus. <b>2015</b> , 52, 709-15	7
142	Diabetic Dyslipidemia. <b>2015</b> , 101-113	1
141	Diabetes and Cardiovascular Disease. <b>2015</b> ,	
140	RETRACTED: Multi-vessel PCI in the type II diabetic: Who are appropriate candidate? Should there be country specific guidelines?. <b>2015</b> , 5, S95-S103	
139	Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals. <b>2015</b> , 262-274	
138	Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study. <b>2015</b> , 6, 339-55	2
137	Atherosclerotic cardiovascular disease in older adults with diabetes mellitus. <b>2015</b> , 31, 29-39, vii	4
136	What the guidelines do not say: statin non-benefit groups. <b>2015</b> , 17, 468	4
135	Comprehensive Management of High Risk Cardiovascular Patients. <b>2016</b> ,	1
134	Complications of Diabetes Mellitus. <b>2016</b> , 1484-1581	11
133	Statins and fibrates as the treatment of nonproliferative diabetic retinopathy in type 2 diabetes mellitus. <b>2016</b> , 30, 111-116	3
132	Factors Influencing Physician Counseling on Cardiovascular Risk. <b>2016</b> , 7, 65-70	

131	Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis. <b>2016</b> , 254, 215-227	20
130	Periodontitis and Diabetes Mellitus: A Complex Relationship. <b>2016</b> , 19-37	
129	Implementation of the American Diabetes Association's Standards of Medical Care post-Medicare Part D: The case of statin utilization in the elderly with diabetes. <b>2016</b> , 12, 419-27	
128	8. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , <b>2016</b> , 39 Suppl 1, S60-71	14.6 196
127	Cardiovascular risk profiles of adults with type-2 diabetes treated at urban hospitals in Riyadh, Saudi Arabia. <b>2016</b> , 6, 29-36	8
126	Type 2 Diabetes. <b>2016</b> ,	2
125	Interplay between proteins and metabolic syndrome-A review. <b>2017</b> , 57, 2483-2496	6
124	Lifestyle change reduces cardiometabolic risk factors and glucagon-like peptide-1 levels in obese first-degree relatives of people with diabetes. <b>2017</b> , 30, 490-498	2
123	Effects of walnut oil on lipid profiles in hyperlipidemic type 2 diabetic patients: a randomized, double-blind, placebo-controlled trial. <b>2017</b> , 7, e259	41
122	Cardiovascular pleiotropic effects of statins and new onset diabetes: is there a common link: do we need to evaluate the role of KATP channels?. <b>2017</b> , 16, 823-831	7
121	9. Cardiovascular Disease and Risk Management. <i>Diabetes Care</i> , <b>2017</b> , 40, S75-S87	14.6 174
120	Effect of Hepatitis C Treatment with Ombitasvir/Paritaprevir/R' Dasabuvir on Renal, Cardiovascular and Metabolic Extrahepatic Manifestations: A Post-Hoc Analysis of Phase 3 Clinical Trials. <b>2017</b> , 6, 515-529	21
119	Modelling cumulative exposure for inference about drug effects in observational studies. <b>2017</b> , 26, 1527-1533	6
118	The American Heart Association Ideal Cardiovascular Health and Incident Type 2 Diabetes Mellitus Among Blacks: The Jackson Heart Study. <b>2017</b> , 6,	30
117	Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study. <b>2017</b> , 17, 135-142	8
116	Diabetes mellitus and stroke: A clinical update. <b>2017</b> , 8, 235-248	64
115	Prevalence of diabetic dyslipidaemia in younger age group. <b>2017</b> , 16, 557-563	2
114	The Evolving Epidemiology of Atherosclerotic Cardiovascular Disease in People with Diabetes. <b>2018</b> , 47, 1-32	12

113	Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus. <b>2018</b> , 43, 68-110	15
112	Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction. <b>2018</b> , 10, 200-212	2
111	9. Cardiovascular Disease and Risk Management:. <i>Diabetes Care</i> , <b>2018</b> , 41, S86-S104	14.6 370
110	Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials. <b>2018</b> , 7, 473-484	5
109	Diabetes and Cardiovascular Disease. <b>2018</b> , 387-393	
108	Pre-diabetes mellitus newly diagnosed after myocardial infarction adversely affects prognosis in patients without known diabetes. <b>2019</b> , 16, 489-497	7
107	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. <b>2019</b> , 104, 1520-1574	146
106	Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan. <b>2019</b> , 26, 890-914	14
105	10. Cardiovascular Disease and Risk Management:. <i>Diabetes Care</i> , <b>2019</b> , 42, S103-S123	14.6 335
104	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. <b>2019</b> , 8, 5-20	9
103	Management of Diabetes Mellitus. <b>2019</b> , 113-177	
102	Obesity-induced impairment of pluripotent stem cells: novel insights into vascular repair strategies. <b>2019</b> , 40, e11-e13	0
101	Effect of a multicomponent intervention on achievement and improvements in quality-of-care indices among people with Type 2 diabetes in South Asia: the CARRS trial. <b>2020</b> , 37, 1825-1831	0
100	Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cross-sectional study (TEMED dyslipidemia study). <b>2020</b> , 19, 237	2
99	Usefulness of estimated average glucose (eAG) in glycemic control and cardiovascular risk reduction. <b>2020</b> , 84, 45-50	2
98	10. Cardiovascular Disease and Risk Management:. <i>Diabetes Care</i> , <b>2020</b> , 43, S111-S134	14.6 296
97	Treating Dyslipidemias in the Primary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults with Diabetes Mellitus. <b>2020</b> , 36, 457-476	2
96	Pharmacological interventions for heart failure in people with chronic kidney disease. <b>2020</b> , 2, CD012466	3

95	10. Cardiovascular Disease and Risk Management:. <i>Diabetes Care</i> , <b>2021</b> , 44, S125-S150	14.6	153
94	A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population: A Danish nationwide cohort study. <b>2021</b> , 23, 2354-2363		0
93	An overview on the biological activity and anti-cancer mechanism of lovastatin. <b>2021</b> , 87, 110122		2
92	Combination Therapy in Type 2 Diabetes.		2
91	Lipids, Atherogenic Dyslipidemia, and Therapy. 347-408		1
90	Diabetes mellitus und das Gerinnungssystem. <b>2005</b> , 40-55		1
89	Advances in lipid-lowering therapy in atherosclerosis. <b>2001</b> , 498, 49-58		8
88	Lipid-Lowering Strategies and Reduction of Coronary Heart Disease Risk. <b>2010</b> , 81-86.e2		1
87	Complications of Diabetes Mellitus. <b>2011</b> , 1462-1551		7
86	Special Patient Populations: Diabetes and Metabolic Syndrome. <b>2009</b> , 443-462		1
85	Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. <b>2002</b> , 43, 706-712		34
84	Lipid Management. <b>2007</b> , 13, 40-47		0
83	Avant-propos Ars longaâudicium difficile . Lâexemple des recommandations dans les dyslipidies du diabtique. <b>2018</b> , 12, 248-254		1
82	Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. <b>2001</b> , 249, 225-35		132
81	Evidence supporting secondary prevention strategies. <b>1999</b> , 14, 303-9		5
80	Preventive cardiology. <b>1999</b> , 14, 382-91		3
79	Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?. <b>2003</b> , 112, 986-8		35
78	Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?. <b>2003</b> , 112, 986-988		93

77	Hyperlipidemia, Diabetes and the Heart. <b>2002</b> , 85-104	1
76	Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetic patients. <b>2008</b> , 23, 22-9	9
75	9. Statins in the treatment and prevention of cardiovascular diseases. <b>2016</b> , 155-178	2
74	Cardiac Outcomes After Myocardial Infarction in Elderly Patients With Diabetes Mellitus. <b>2002</b> , 11, 504-519	13
73	Diabetes as "Coronary Artery Disease Risk Equivalent": A Historical Perspective. <b>2017</b> , 18, 34-37	14
72	American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control*. <b>2002</b> , 8, 5-11	80
71	Relationship between insulin resistance and effect of atorvastatin in non-diabetic subjects. <b>2005</b> , 12, 9-13	7
70	Therapie des Diabetes mellitus. <b>2000</b> , 459-503	
69	Glukose. <b>2001</b> , 605-805	
68	Coronary Atherosclerosis: Chronic Coronary Syndromes. <b>2002</b> , 779-820	
67	Diabetes: A Growing CHD Epidemic. <b>2002</b> , 109-114	
66	Vascular Disease in Diabetes Mellitus. <b>2002</b> , 995-1008	
65	Special Therapeutic Considerations. <b>2002</b> , 231-257	
64	Management of Patients with Diabetes and Coronary Artery Disease. <b>2002</b> , 185-209	1
63	Types of Diabetes and Their Implications Regarding Heart and Vascular Disease. <b>2002</b> , 9-33	1
62	Management of type 2 diabetes. <b>2002</b> , 1-24	
61	Hypercholesterolemia and Cardiovascular Risk in Diabetic Patients. <b>2003</b> , 109-117	
60	Lipidkorigiruyushchie efekty nizkoy dozy atorvastatina u bol'nykh sakharnym diabetom tipa 2 i ozhireniem. <b>2003</b> , 6, 30-34	

- 59 Clinical Features and Treatment of Coronary Heart Disease in Diabetes.
- 58 Guidelines for clinical use of the statins. **2003**, 200-212
- 57 Coronary Artery Disease and Cardiomyopathy. **2004**, 685-700
- 56 Dyslipoproteinemia. **2004**, 367-376
- 55 Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus. **2004**, 487-516
- 54 Hypolipidemic Agents and Their Role in the Therapy of Diabetes Mellitus.
- 53 Opções terapêuticas atuais para diabetes mellitus tipo 2 e doença arterial coronariana: prevenção secundária intensiva focada no treinamento físico versus revascularização percutânea ou cirúrgica. **2004**, 10, 220-223
- 52 Bedside Platelet Monitoring. **2004**, 495-520
- 51 Statins and Plaque Stabilization. **2004**, 521-562
- 50 Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events. **2005**, 543-556
- 49 Stroke Prevention, Blood Cholesterol and Statins. *Neurological Disease and Therapy*, **2005**, 123-150
- 48 Stroke Prevention. *Fundamental and Clinical Cardiology*, **2006**, 545-584
- 47 Type 2 Diabetes. *Fundamental and Clinical Cardiology*, **2006**, 187-254
- 46 Lowering Low-Density Lipoprotein Cholesterol Levels to Reduce Atherosclerotic Coronary Heart Disease Risk. **2007**, 221-240
- 45 Management of Cholesterol Disorders. **2007**, 2667-2691
- 44 High Density Lipoprotein Cholesterol Comes of Age. *Korean Circulation Journal*, **2007**, 37, 187 2.2 2
- 43 Dyslipidemia and Diabetes. **2007**, 405-416
- 42 Cholesterol Management in Patients with Chronic Kidney Disease. **2008**, 715-724

- 41 Korrektsiya narusheniy lipidnogo obmena u bol'nykh sakharnym diabetom tipa 2. *Systemic Hypertension*, **2008**, 5, 63-66 1.6
- 40 Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus and Metabolic Syndrome. **2009**, 279-317
- 39 Nutrition, Metabolic Syndrome, and Diabetes in the Senior Years. **2010**, 389-417 1
- 38 Diabetes and Cardiovascular Disease. **2010**, 299-304
- 37 Therapeutic Regulation of High-Density Lipoprotein Transport in the Metabolic Syndrome. **2010**, 157-163
- 36 Trattamento farmacologico. **2010**, 89-98
- 35 Diabetic Dyslipidemia. **2011**, 213-238 1
- 34 Are Statins the Optimal Therapy for Cardiovascular Risk in Patients with Diabetes? Are Triglycerides an Important Independent Risk Factor for Diabetes?. 116-126
- 33 Diabetes and Coronary Heart Disease. **2012**, 471-484
- 32 Diabetes und koronare Herzkrankheit. **1999**, 345-418
- 31 Diabetes Mellitus: Alterations in Vessel Wall Properties. **2015**, 221-236
- 30 The effect of intensive therapy of atorvastatin on vascular rigidity and lipid profile in patients with ST-segment elevation myocardial infarction. *Arterial Hypertension (Russian Federation)*, **2018**, 24, 406-415<sup>0.7</sup>
- 29 Therapeutic Effects of Fenofibrate on Blood Serum Lipid in Type II Diabetic Patients in El-beida, Libya. *Mag allat Al-Muhtar Li-l-?ulm*, **2019**, 34, 146-152 0
- 28 Hydrophilic vs. Lipophilic Statins in Diabetic Patients - Comparison of Long-Term Outcomes After Acute Myocardial Infarction. *Circulation Reports*, **2020**, 2, 280-287 0.7
- 27 Statins, diabetic oxidative stress, and vascular tissue. **2020**, 333-341
- 26 Heart Failure, Atrial Fibrillation, and Diabetes Mellitus. **2007**, 77-88
- 25 Lipide. **2005**, 362-377
- 24 Diabetes Mellitus. **2005**, 563-575

23	Dyslipidemia Associated With Diabetes and Insulin Resistance Syndromes. <b>2006</b> , 193-212		
22	Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. <b>2006</b> , 113-143		
21	Epidemiology and Prevention of Cardiovascular Disease in Diabetes. <b>2009</b> , 19-33		
20	Insulin Resistance and Cardiovascular Disease. <b>2008</b> , 207-228		
19	Lipoproteins in Diabetes: Risk and Opportunity. <b>2008</b> , 265-288		
18	Insulin resistance and vessel endothelial function. <i>Journal of the Royal Society of Medicine</i> , <b>2002</b> , 95 Suppl 42, 54-61	2.3	1
17	Advances in diabetes for the millennium: the heart and diabetes. <i>MedGenMed: Medscape General Medicine</i> , <b>2004</b> , 6, 7		
16	Advances in diabetes for the millennium: diabetes and cholesterol. <i>MedGenMed: Medscape General Medicine</i> , <b>2004</b> , 6, 5		
15	PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study. <i>Vascular Health and Risk Management</i> , <b>2007</b> , 3, 355-70	4.4	26
14	Statins in type 2 diabetes mellitus: target on lipids and vascular wall function. <i>Netherlands Heart Journal</i> , <b>2003</b> , 11, 123-128	2.2	
13	Diabetes care and health status of First Nations individuals with type 2 diabetes in Alberta. <i>Canadian Family Physician</i> , <b>2009</b> , 55, 386-93	0.9	26
12	Diabetes & coronary heart disease: current perspectives. <i>Indian Journal of Medical Research</i> , <b>2010</b> , 132, 584-97	2.9	27
11	Process of care compliance is associated with fewer diabetes complications. <i>American Journal of Managed Care</i> , <b>2014</b> , 20, 41-52	2.1	11
10	Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. <i>Revista Espanola De Cardiologia Suplementos</i> , <b>2011</b> , 11, 29-35	0.2	
9	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.. <i>Diabetes Care</i> , <b>2022</b> , 45, S144-S174	14.6	46
8	Circulating Cytokines in Myocardial Infarction Are Associated With Coronary Blood Flow.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 837642	8.4	0
7	Statin use and the risk of CVD events, stroke, and all-cause mortality in patients with diabetes: a systematic review and meta-analysis. <b>2022</b> ,		0
6	LIPID DISORDERS IN TYPE 2 DIABETES. <b>2001</b> , 36, 291-302		0



5	Cardiovascular Diseases and Nutraceuticals: Underlying Mechanism and Therapeutic Biomarkers. <b>2022</b> , 1-24	o
4	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetesâ2023. <b>2023</b> , 46, S158-S190	7
3	Measuring the Quality of Care of Diabetic Patients at the Specialist Outpatient Clinics in Public Hospitals in Singapore. <b>2007</b> , 36, 980-986	o
2	Effects of Statin Dose, Class, and Use Intensity on All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. <b>2023</b> , 16, 507	o
1	Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study. <b>2023</b> , 79, 687-700	o